Cardarine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Powys ( POH-iss, POW-iss, Welsh: [ˈpou̯ɪs]) is a county and preserved county in Wales. It borders Gwynedd, Denbighshire and Wrexham to the north; the English ceremonial counties of Shropshire and Herefordshire to the east; Monmouthshire, Blaenau Gwent, Merthyr Tydfil, Caerphilly, Rhondda Cynon Taf and Neath Port Talbot to the south; and Carmarthenshire and Ceredigion to the west. The largest settlement is Newtown, and the administrative centre is Llandrindod Wells. Powys is the largest and most sparsely populated county in Wales, having an area of 5,181 km2 (2,000 sq mi) and a population of 134,843 in 2025. While largely rural, its towns include Welshpool in the north-east, Newtown in the north-centre, Llandrindod Wells in the south-centre, Brecon in the south, Ystradgynlais in the far south-west, and Machynlleth in the far west. The Welsh language can be spoken by 16.4% of the population. The boundaries of Powys largely follow those of the historic counties of Montgomeryshire, Radnorshire, and Brecknockshire. The county is predominantly hilly and mountainous. To the west lie the Cambrian Mountains, where the River Severn and River Wye both have their source on the Powys side of the Plynlimon massif; together with their tributaries they drain most of the county. The southern quarter of Powys contains, from east to west, part of the Black Mountains, the Brecon Beacons, Fforest Fawr, and part of the Black Mountains, all of which are part of Brecon Beacons National Park. Further north are two more upland areas, Mynydd Epynt and Radnor Forest.
== Further reading == Davidson, Alan (1999). "Isinglass". Oxford Companion to Food. Oxford University Press. p. 407. ISBN 0-19-211579-0. Woods, Chris (1995). "Conservation Treatments for Parchment Documents", Journal of the Society of Archivists, Vol. 16, Issue 2, pp. 221–239. Chemozyme Archived 21 September 2018 at the Wayback Machine
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash. Ribociclib was approved for medical use in the United States in March 2017, in the European Union in August 2017, and in the United Kingdom in February 2021.
=== Energy === As governor, González created a task force to evaluate Puerto Rico’s energy policy and identify alternatives to LUMA Energy, the primary electricity provider on the island. She appointed Josué Colón Ortiz as the Energy Czar and has said she wants to expand the use of liquefied natural gas, potentially revising renewable energy targets, while also backing policies that allow individual solar energy producers to sell excess power to the grid. In December 2024, she stated her intent to replace LUMA with a different private operator. However, canceling the contract could lead to legal disputes, with estimated termination costs ranging from $300 million to $600 million. Reverting the system to the Puerto Rico Electric Power Authority (PREPA), which is in the process of being dismantled, could also cause service disruptions and require a transition period. Finding another private operator may present challenges, as potential candidates could demand higher compensation, and few companies may be willing to take on the responsibility. González has been critical of LUMA, stating that requiring agencies to pursue legal action before proceeding with energy-related work “only delays these processes even further, does not provide electricity to any home or any industrial plant, and puts a risk to the funding.” In May 2025, Jennifer Gonzalez Colón supported an investment project to install battery-powered solar systems in clinics and public housing in Puerto Rico.
Anoop's father, who was the Minister for Food and Civil Supplies, died on 30 October 2011. Following this, Anoop was nominated by the Kerala Congress (Jacob) and UDF to contest from the Piravom assembly seat previously represented by his father. His father had lost the sitting seat in 2006 elections and recaptured it in 2011 election by a margin of 157 votes. Against Anoop Jacob, CPI(M)–led LDF once again fielded M. J. Jacob, who had won against T. M. Jacob in 2006 and lost in 2011. Since the result of Piravom by-election mattered heavily to the ruling UDF who had a slender margin of 1 seat in the Legislative assembly over LDF, the constituency witnessed intense campaigning from both sides. Election was held on 17 March 2012 and results were announced on 21 March 2012. Anoop Jacob won the by-election by a significant margin of 12,071 votes. He was sworn in as an MLA on 22 March 2012. Anoop took oath as the Minister for Food & Civil Supplies on 12 April 2012 and occupied office in the North Block of the Kerala Secretariat; both portfolio & office last held by his departed father.
Sources: en.wikipedia.org
In 2008, IGN ranked Ueda as one of their top 100 game creators of all time, saying that his knack for "creating atmospheric puzzle playgrounds with mute or near-mute characters instills a sense of isolation, yet provides an endearing feeling of hope as the protagonists seek simply to find an exodus or redemption from their weather-worn, ornate prisons".
==== P-Glycoprotein inhibition ==== Bicalutamide, as well as enzalutamide, have been found to act as inhibitors of P-glycoprotein efflux and ATPase activity. This action may reverse docetaxel resistance in prostate cancer cells by reducing transport of the drug out of these cells.
== Regulatory scrutiny == The Royal Australian College of General Practitioners (RACGP) raised concerns in 2023 about telehealth services using remote questionnaires to prescribe GLP-1 receptor agonists, questioning whether such methods provided adequate clinical assessment. The Therapeutic Goods Administration (TGA) warned telehealth companies against advertising prescription-only medicines directly to consumers. During GLP-1 medication shortages in 2023–2024, Eucalyptus partnered with compounding pharmacies to provide compounded semaglutide. This practice drew criticism from pharmaceutical manufacturers and regulators. The Australian federal government subsequently banned pharmacy compounding of GLP-1 drugs from October 2024. Media reports in The Sydney Morning Herald and The Australian questioned whether social media and influencer campaigns for Eucalyptus brands overstated treatment results. ABC's Media Watch raised concerns about whether television segments promoting the company's services blurred editorial and advertising boundaries. In response to regulatory concerns, Eucalyptus introduced phone-based GP consultations to replace asynchronous online forms. In June 2025, the TGA issued class-wide safety warnings for all GLP-1 and dual GIP/GLP-1 receptor agonists, including medications prescribed through Juniper, regarding aspiration risks during general anaesthesia. The warnings required updates to product information across all suppliers of these medications.
The Tolkiens had four children: John Francis Reuel Tolkien (17 November 1917 – 22 January 2003), Michael Hilary Reuel Tolkien (22 October 1920 – 27 February 1984), Christopher John Reuel Tolkien (21 November 1924 – 16 January 2020) and Priscilla Mary Anne Reuel Tolkien (18 June 1929 – 28 February 2022). Tolkien was very devoted to his children and sent them illustrated letters from Father Christmas when they were young.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.